Chuck  Ence net worth and biography

Chuck Ence Biography and Net Worth

Chief Accounting and Compliance Officer of Relmada Therapeutics

Charles Ence is currently our Chief Accounting and Compliance Officer. From August 2003 until June 2019, Mr. Ence was Chief Financial Officer/Corporate Controller of New Age Beverages Corp/Xing Beverages, LLC located in Denver, Colorado. He managed all the financial affairs of New Age and their other portfolio companies helping lead the firm into becoming one of the top 100 non-alcoholic beverage companies worldwide. He helped guide the expansion of the business to ultimately penetration of 46 states domestically and 10 countries internationally, with consistent growth and profitability throughout his tenure. Mr. Ence was also instrumental in successfully uplisting the company onto the NASDAQ capital market. Prior to New Age, Mr. Ence was a senior executive, Planning Manager and Director of Finance for Quantum Corp. Following Quantum he served as a Director of Finance and Investor Relations at On Command Corp. Mr. Ence began his career at PepsiCo. During his 12 years at PepsiCo, Mr. Ence served as a financial analyst, planning supervisor, planning and analysis manager and ultimately controller.

He received his Bachelor of Arts in Business Administration and Accounting from Southern Utah University in 1984, and obtained a Masters in Business Administration in Finance from Arizona State University School of Business in 1985.

What is Chuck Ence's net worth?

The estimated net worth of Chuck Ence is at least $2.69 million as of November 5th, 2025. Mr. Ence owns 403,931 shares of Relmada Therapeutics stock worth more than $2,690,180 as of March 25th. This net worth estimate does not reflect any other investments that Mr. Ence may own. Learn More about Chuck Ence's net worth.

How do I contact Chuck Ence?

The corporate mailing address for Mr. Ence and other Relmada Therapeutics executives is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. Relmada Therapeutics can also be reached via phone at (786) 629-1376 and via email at [email protected]. Learn More on Chuck Ence's contact information.

Has Chuck Ence been buying or selling shares of Relmada Therapeutics?

Chuck Ence has not been actively trading shares of Relmada Therapeutics during the last quarter. Most recently, on Wednesday, November 5th, Chuck Ence bought 136,000 shares of Relmada Therapeutics stock. The stock was acquired at an average cost of $2.20 per share, with a total value of $299,200.00. Following the completion of the transaction, the chief operating officer now directly owns 403,931 shares of the company's stock, valued at $888,648.20. Learn More on Chuck Ence's trading history.

Who are Relmada Therapeutics' active insiders?

Relmada Therapeutics' insider roster includes Charles Casamento (Director), Chuck Ence (Chief Accounting and Compliance Officer), and Maged Shenouda (CFO). Learn More on Relmada Therapeutics' active insiders.

Are insiders buying or selling shares of Relmada Therapeutics?

In the last twelve months, Relmada Therapeutics insiders bought shares 9 times. They purchased a total of 1,366,626 shares worth more than $1,931,592.25. The most recent insider tranaction occured on December, 15th when CFO Maged Shenouda bought 11,665 shares worth more than $48,059.80. Insiders at Relmada Therapeutics own 20.7% of the company. Learn More about insider trades at Relmada Therapeutics.

Information on this page was last updated on 12/15/2025.

Chuck Ence Insider Trading History at Relmada Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/5/2025Buy136,000$2.20$299,200.00403,931View SEC Filing Icon  
5/16/2025Buy228,961$0.45$103,032.45267,931View SEC Filing Icon  
1/30/2024Buy14,500$3.87$56,115.0025,300View SEC Filing Icon  
See Full Table

Chuck Ence Buying and Selling Activity at Relmada Therapeutics

This chart shows Chuck Ence's buying and selling at Relmada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Relmada Therapeutics Company Overview

Relmada Therapeutics logo
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Read More

Today's Range

Now: $6.58
Low: $6.19
High: $6.74

50 Day Range

MA: $4.58
Low: $3.55
High: $7.01

2 Week Range

Now: $6.58
Low: $0.24
High: $7.51

Volume

1,391,406 shs

Average Volume

1,555,888 shs

Market Capitalization

$482.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72